share_log

康寧傑瑞製藥-B：截至二零二四年四月三十日止月份之股份發行人的證券變動月報表

ALPHAMAB-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2024

Hong Kong Stock Exchange ·  May 7 16:49
Summary by Futu AI
康宁杰瑞制药（ALPHAMAB）於2024年5月7日向香港交易及結算所有限公司提交了最新的證券變動月報表，報告截至2024年4月30日的公司股份變動情況。報告顯示，公司的法定/註冊股本及已發行股份在本月內均無變動，普通股的結存數量維持在25,100,000,000股，而已發行股份結存數量為964,843,807股。此外，公司的股份期權計劃包括首次公開發售前後的購股權計劃，但本月內並無股份期權行使，因此沒有新股份發行。報告亦確認，所有證券發行均已獲得董事會授權，並符合香港聯合交易所有限公司證券上市規則的相關要求。
康宁杰瑞制药（ALPHAMAB）於2024年5月7日向香港交易及結算所有限公司提交了最新的證券變動月報表，報告截至2024年4月30日的公司股份變動情況。報告顯示，公司的法定/註冊股本及已發行股份在本月內均無變動，普通股的結存數量維持在25,100,000,000股，而已發行股份結存數量為964,843,807股。此外，公司的股份期權計劃包括首次公開發售前後的購股權計劃，但本月內並無股份期權行使，因此沒有新股份發行。報告亦確認，所有證券發行均已獲得董事會授權，並符合香港聯合交易所有限公司證券上市規則的相關要求。
CONNING GERRY PHARMACEUTICALS (ALPHAMAB) FILED WITH HONG KONG TRADING AND SETTLEMENT LIMITED ON 7 MAY 2024 WITH HONG KONG TRADING AND SETTLEMENT HOLDINGS LIMITED REPORTING THE CHANGES IN COMPANY SHARES FOR THE YEAR ENDED 30 APRIL 2024. The report shows that the company's regulary/registered share capital and issued shares remained unchanged during the month, with the depositing volume of ordinary shares remaining at 25,100,000,000 shares and the issued shares at 964,843,807 shares. In addition, the company's stock option plan includes a pre- and post-IPO share option plan, but no stock options were exercised this month, so no new shares were issued. The report also confirms that all securities issuance has been authorised by the Board and complies with the relevant requirements of the Securities Listing Rules of the Hong Kong Stock Exchange Limited.
CONNING GERRY PHARMACEUTICALS (ALPHAMAB) FILED WITH HONG KONG TRADING AND SETTLEMENT LIMITED ON 7 MAY 2024 WITH HONG KONG TRADING AND SETTLEMENT HOLDINGS LIMITED REPORTING THE CHANGES IN COMPANY SHARES FOR THE YEAR ENDED 30 APRIL 2024. The report shows that the company's regulary/registered share capital and issued shares remained unchanged during the month, with the depositing volume of ordinary shares remaining at 25,100,000,000 shares and the issued shares at 964,843,807 shares. In addition, the company's stock option plan includes a pre- and post-IPO share option plan, but no stock options were exercised this month, so no new shares were issued. The report also confirms that all securities issuance has been authorised by the Board and complies with the relevant requirements of the Securities Listing Rules of the Hong Kong Stock Exchange Limited.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.